iktos

🔬 Drug Target Review, just published an interview with Yann Gaston-Mathe, Co-founder & CEO of iktos, discussing how chemistry-aware GenAI is reshaping the landscape of small molecule design. The article highlights how combining deep chemical expertise with generative AI can accelerate the path from idea to synthesis — bridging the gap between in silico design and experimental reality. 🧬 Iktos’s Makya solution uniquely integrates synthetic feasibility directly into the generative process — designing molecules through realistic reaction steps using available starting materials. This approach enables the exploration of novel chemical space while ensuring that proposed compounds are synthetically accessible and relevant for medicinal chemistry programs. 💡 > “AI should not replace chemists — it should empower them to explore chemical space more efficiently and creatively.” 📖 Read the full article: https://lnkd.in/erRY3m5H #AIinDrugDiscovery #GenerativeAI #MedicinalChemistry #DrugDesign #SyntheticFeasibility #Iktos #Makya

🔬 Drug Target Review, just published an interview with Yann Gaston-Mathe, Co-founder & CEO of iktos, discussing how chemistry-aware GenAI is reshaping the landscape of small molecule design. The article highlights how combining deep chemical expertise with generative AI can accelerate the path from idea to synthesis — bridging the gap between in silico design and experimental reality. 🧬 Iktos’s Makya solution uniquely integrates synthetic feasibility directly into the generative process — designing molecules through realistic reaction steps using available starting materials. This approach enables the exploration of novel chemical space while ensuring that proposed compounds are synthetically accessible and relevant for medicinal chemistry programs. 💡 > “AI should not replace chemists — it should empower them to explore chemical space more efficiently and creatively.” 📖 Read the full article: https://lnkd.in/erRY3m5H #AIinDrugDiscovery #GenerativeAI #MedicinalChemistry #DrugDesign #SyntheticFeasibility #Iktos #Makya

🧬 This year’s The Nobel Prize in Physiology or Medicine celebrates the groundbreaking discovery of how the immune system maintains balance through regulatory T cells (Tregs) and the FOXP3 gene — a fundamental advance that has reshaped our understanding of immune tolerance and autoimmunity. The 2025 award honors Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their pioneering contributions. At iktos, we’re proud to be contributing to the next chapter of this story. 👉 Our in-house discovery program targeting MTHFD2 explores a novel metabolic checkpoint that controls effector and regulatory T cell fate and function: https://iktos.ai/pipeline 🛠️ By inhibiting MTHFD2, we aim to promote Treg "like" phenotype over pro-inflammatory CD4+ T cell subsets — opening a promising therapeutic avenue for chronic inflammatory and autoimmune diseases. The Nobel recognition highlights how fundamental discoveries can transform medicine. At Iktos, we’re building on that legacy — combining deep biological insight with our AI and robotics-enabled drug discovery platform to translate new mechanisms into real therapeutic opportunities. Read about the 2025 Nobel Prize in Physiology or Medicine: https://lnkd.in/g8F7Kyh #NobelPrize #Immunology #DrugDiscovery #Inflammation #AutoimmuneDiseases

🚀 We are pushing the frontiers of automated chemistry! “Thinking Outside the Library: Cluster Synthesis of Diverse Molecules on a Single Robotic Platform.”🧪 You can now read our latest work, available as a preprint on ChemRxiv. This study showcases our Iktos Robotics platform, developed through a remarkable interdisciplinary effort over the past three years. The work demonstrates—for the first time—the ability to batch and cluster different types of chemical reactions in parallel within the same reactor. We this work, we redefine how to think about synthesis automation, opening new possibilities for unprecedented acceleration of small molecule discovery. Our team developed a fully integrated system that combines: 🧬 Makya: De-novo generation to define the Robotics Chemical Space 🧩 Spaya API: AI-guided retrosynthesis w/robotic constraints 🧠 Unified robotics OS with multi-layer scheduling ⚙️ Ilaka: decision-making and data-structuring interface, connected to a real-time procurement systems. This achievement reflects Iktos’s commitment to merging AI, robotics, and chemistry to accelerate and expand the boundaries of drug discovery. It also exemplifies the bold innovation that recently earned Iktos a prestigious European Innovation Council (EIC) grant, supporting our continued efforts to advance and scale our robotics platform. 👉 Read the article here: https://lnkd.in/gNz7rUz8 👏 Congratulations to the authors Franck Le Vaillant, Luidgi Gromat, Clémentine Pescheteau, Nicolas Ducrot, Aurélien Demilly, Jean-Christophe Meillon, Nicolas Do Huu, PhD and Quentin Perron!

Excited to reconnect with industry peers in AI and pharma at Princeton University via BioNJ on Oct 9! Looking forward to engaging discussions and networking opportunities. #AI #Pharma #BioNJ #Networking

🇯🇵 We’re pleased to share that Victoire M. L. Cachoux and Hideyoshi Fuji will be attending BioJapan 2025 in Yokohama, Japan, from October 8th to 10th. As a pioneer in Generative AI and robotics for drug discovery, iktos is redefining how new medicines are designed, synthesized, and optimized. With a proven technology platform and successful collaborations, Iktos stands out as one of the most exciting partners in AI-driven drug discovery. 💬 If you’re attending, don’t miss the chance to meet Victoire and Hideyoshi and learn more about Iktos’s AI-driven drug discovery platform! 👉 Learn more about the event: https://jcd-expo.jp/en/ #Iktos #AI #DrugDiscovery #BioJapan #LifeSciences #Collaboration #HealthcareInnovation #Japan

🎤 We’re pleased to announce that Hideyoshi Fuji will be speaking at the Healthcare Conference – Business Leaders Forum 2025, taking place on October 7th, 2025, in Tokyo, Japan 🇯🇵. Hideyoshi will join distinguished leaders to discuss “Partnering for success: Euro-Japanese alliances”, exploring opportunities for collaboration and innovation between the European and Japanese healthcare sectors. Organized by the French Chamber of Commerce and Industry in Japan (CCI France Japon), this event gathers healthcare business leaders and innovators to exchange insights and foster new partnerships between Europe and Japan. 🔗 Learn more about the conference: https://lnkd.in/eePfF-cy We look forward to inspiring conversations and new partnerships that drive healthcare innovation forward! #Healthcare #Innovation #BusinessLeadership #HealthTech #Japan #Europe #CCIFJ #Conference #Collaboration

📢 We’re excited to share that our Co-Founder & CEO, Yann Gaston-Mathe, is attending the 12th Annual HealthTech Investment Forum (#Sachs_HTIF) — part of Sachs Associates Autumn Life Sciences Week (#SALSW) in Basel! As a pioneer in Generative AI and robotics for drug discovery, iktos is redefining how new medicines are designed, synthesized, and optimized. With a proven technology platform, successful partnerships, and ambitious growth plans, Iktos stands out as one of the most exciting prospects in AI-driven drug discovery. 💬 If you’re attending, connect with Yann to discuss how AI can unlock new opportunities for innovation and investment in #HealthTech and #LifeSciences. 🔗 More information: https://lnkd.in/dg4NzC9U #HealthTech #MedTech #DrugDiscovery #AI #GenerativeAI

Are you attending BioTechX in Basel this week? Stop by Booth #128 to meet the Iktos team - Ashiq H. Khan, Chief Business Officer, and Nicolas Martin, PhD, Business Development Director Europe. Discover how Generative AI is transforming drug discovery — from de novo molecular design to AI-driven robotic synthesis. 💬 Whether you’re curious about our SaaS platforms Makya and Spaya, or want to explore partnership opportunities, we’d love to connect and exchange ideas! 👋 Come say hi — our team looks forward to seeing you there! #BioTechX #DrugDiscovery #GenerativeAI #PharmaInnovation